# Study of Pentasa® for Reducing Residual Systemic Immune Activation in Treated HIV Infection

> **NCT03399903** · PHASE1,PHASE2 · COMPLETED · sponsor: **AIDS Healthcare Foundation** · enrollment: 47 (actual)

## Conditions studied

- HIV-1-infection
- Gut Inflammation

## Interventions

- **DRUG:** Pentasa vs Align

## Key facts

- **NCT ID:** NCT03399903
- **Lead sponsor:** AIDS Healthcare Foundation
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-05-01
- **Primary completion:** 2019-03-22
- **Final completion:** 2019-03-22
- **Target enrollment:** 47 (ACTUAL)
- **Last updated:** 2020-03-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03399903

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03399903, "Study of Pentasa® for Reducing Residual Systemic Immune Activation in Treated HIV Infection". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03399903. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*